[Edaily Reporter Park Jung-Soo ] ORIENTBIO(002630)announced on the 29th that key agenda items, including the approval of financial statements, were passed as proposed at its 69th Annual General Meeting of Shareholders. The company plans to focus on enhancing corporate value by strengthening financial soundness and securing growth engines for new businesses.
ORIENTBIO is expanding its bio-infrastructure business based on Korea’s only International Genetic Standardization (IGS) laboratory animal production system. Through technical cooperation with Charles River in the U.S., the company is ensuring a stable supply of international-standard laboratory animals, and it is also strengthening its capacity to supply high-quality laboratory animals by expanding operations at its Specific Pathogen-Free (SPF) rabbit production facility in Jeongeup.
At the same time, the company is continuing clinical trials and formulation technology research for its hair-regrowth drug candidate, “OND-1.” It has registered patents in South Korea and Japan and is securing patents in other major countries as well.
A company official stated, “The recently announced capital policy is not merely a financial restructuring but part of a strategy to lay the groundwork for mid- to long-term growth,” adding, “We will continue to build a foundation for sustainable growth by strengthening our R&D capabilities and expanding our BioInfra Co.,Ltd. infrastructure.” The official further noted, “We will continue to practice responsible management based on trust with our shareholders.”